MediPrint® Ophthalmics Announces Promising Results from Its SIGHT-2 Phase 2b Group 1 Clinical Study
Human Trial with Novel Glaucoma Treatment Rendered a Clinically Meaningful
Human Trial with Novel Glaucoma Treatment Rendered a Clinically Meaningful
Company Also Announces Move into New San Diego Headquarters SAN
Plus, Company Comments on Its Poster at Prestigious American Glaucoma
Plus, Company Advances Plans for Phase 2b Trial in 2022
Plus, Company Receives Patent for Novel Post-Cataract Surgery Lens SAN
The Coming Rise of Drug-delivery Contact Lenses This novel new
Plus, Company Spotlights its Successful First-in-human Clinical Study Results
First-in-human Trial with Novel Glaucoma Treatment Confirmed Favorable Safety
IND Paves the Way to Phase 2a Clinical Study